Volume 11 Supplement 1

Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection

Open Access

Different metabolic and anthropometric characteristics of TVD, CBV or KVX associated with nevirapine: Results from the "NEVIRAPINE COMPANION" cohort

  • G Guaraldi1,
  • F Adorni1,
  • S Zona1,
  • N Squillace1,
  • G Orlando1,
  • C Stentarelli1,
  • R Esposito1 and
  • C Sconiamilio1
Journal of the International AIDS Society200811(Suppl 1):P34

https://doi.org/10.1186/1758-2652-11-S1-P34

Published: 10 November 2008

Purpose of the study

To assess metabolic, anthropometric and cardiovascular risk profile of a cohort undergoing stable nevirapine therapy associated with TDF+FTC (TVD), AZT+3TC (CBV) or ABC+3TC (KVX).

Methods

Cross-sectional observational study that included all consecutive HIV-infected patients seen at a metabolic clinic undergoing nevirapine therapy for >6 months associated with TVD, CBV or KVX.

Summary of results

244 patients were included. Table 1.

Table 1

Median* or %°

Total

TVD n = 142 pts

CBV n = 62 pts

KVX n = 40 pts

p-value

Age, (yrs)*

44.0

44.5

42.0

44.0

.173

CDC Group C°

25.8

25.4

18

9

.793

Nadir CD4 (c/μL)*

156

141

166

188

.457

NRTI cum exp (mths)*

119

132

112

126

.073

Current NRTI Tx (mths)*

18.1

12.3

24.9

21.7

<.001

PI cum exp (mths)*

42

47

36

38

.100

NNRTI cum exp (mths)*

45

40

52

55

.038

Current NEV Tx (mths)*

20

13.4

24.9

21.8

.003

BMI

22.5

22.5

23.55

21.54

.020

Waist (cm)*

83

83

87

80

.009

Total fat mass (gr)*

9905

9538

11926

8656

.012

Total lean mass (gr)*

50754

51590

50754

45940

.257

% fat in legs*

9.14

9.10

12.01

7.43

.080

% fat in legs/BMI*

0.40

0.41

0.48

0.35

.239

HOMA

2.79

2.78

2.78

2.82

.993

TG (mg/dL)*

130

120

133

142

.200

TC (mg/dL)*

199

194

196

215

.040

HDL (mg/dL)*

49

49

51

48

.120

LDL (mg/dL)*

123

122

113

137

.028

ApoB (mg/dL)*

102

99

94.5

115.5

.009

ApoA1 (mg/dL)*

151

146

163.5

157

<.001

Rho of Spearman did not find any correlation between NVP exposure and the surrogate toxicity end-points (all: p = ns).

Conclusion

KVX arm displayed a greater pro-atherogenic risk profile notwithstanding lower BMI in respect to CBV and TVD. This non-randomised cohort cannot discriminate if patients with a higher underlying risk of cardiovascular disease might be initially placed on KVX or if KVX associated with NVP per se, had a poorer metabolic profile compared with the TVD and CBV arms. Careful assessment of metabolic parameters should be evaluated in people undergoing the association KVX+NEV even beyond the initial 6 months of therapy and appropriate lipid-lowering therapy started if needed.

Authors’ Affiliations

(1)
University of Modena and Reggio Emilia

Copyright

© Guaraldi et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement